CD8A and cancer: TAg-specific CD40L+IFN-γ+CD8+ T cells coexpressed more interleukin-2 (IL-2) as compared to TAg-specific CD40L−IFN-γ+CD8+ T cells (Fig. 1C) and remained present after rejection of cancer cells at day 38.